Completed PHASE4 INTERVENTIONAL 2-arm NCT01172418

Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols

Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols Accompanied by Maintenance Therapy With Prograf® and Myfortic®

Sponsor: University of Miami

Conditions Transplant; Failure, Kidney

Interventions Alemtuzumab Daclizumab Thymoglobulin

Updated 9 times since 2017 Last updated: Sep 25, 2023 Started: Feb 28, 2006 Primary completion: May 31, 2010 Completion: May 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Transplant; Failure, Kidney and is currently completed. University of Miami leads this study, which shows 9 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Oct 2023 — Jul 2024 [monthly]

Completed PHASE4
Jan 2023 — Oct 2023 [monthly]

Completed PHASE4
Dec 2022 — Jan 2023 [monthly]

Completed PHASE4

▶ Show 4 earlier versions

Jan 2021 — Dec 2022 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jul 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Jul 2017 [monthly]

Completed PHASE4

First recorded

Feb 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Miami

Data source: University of Miami

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Miami, United States